Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology presented interim results of its Phase II CONTROL Trial of PB272 (Neratinib) in extended adjuvant treatment of HER2-positive early stage breast cancer at the AACR Annual Meeting.

Puma Biotechnology, Inc.